[Skip to Content]
[Skip to Content Landing]
Editor's Correspondence
February 14, 2000

Virologic Response Associated With a Change in Protease Inhibitor Therapy

Author Affiliations

Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000

Arch Intern Med. 2000;160(3):393-394. doi:

In the report by Guardiola and colleagues,1 a switch in protease inhibitor (PI) therapy for reasons other than therapeutic failure occurred in 74% of patients who were treated with PI-based regimens. The therapeutic strategy in these patients needs careful assessment before PI changes, since the patients may be put at greater risk for therapeutic failure after therapy change.